影視股高開 春節檔總票房突破60億元創歷史記錄
格隆匯2月16日丨影視股高開,IMAX中國和貓眼娛樂均高開逾14%,阿里影業高開10.28%。

春節檔電影票房連續四日超10億元,總票房突破60億元,超越2019年春節檔的59.05億元總票房,成為史上最強春節檔。
其中,《唐人街探案3》上映4天總票房突破30億元,創中國電影市場最快破30億紀錄,成為繼《八佰》之後,中國影史第11部破30億影片;《你好,李煥英》票房超18億排名第二,第三名《刺殺小説家》票房突破4億。
今年春節檔也是首次同時上映兩部IMAX特製拍攝的電影,其中包括全片使用IMAX攝影機拍攝的《唐人街探案3》和超過一個小時以IMAX特殊畫幅呈現的《刺殺小説家》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.